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Do the salivary glands of patients with systemic 
sclerosis show ultrasonographic modifications 
suggestive of Sjögren's syndrome?
The paper by Ferdowsi et al, reported a 23-item composite 
damage index to quantify organ damage in systemic sclerosis 
(SSc).1 In this index, sicca symptoms (item 3) play an important 
role (weight score=3). Actually, sicca symptoms are frequently 
reported by patients with SSc (7.5%–68%) and could be due 
to a fibrosis process of the salivary glands (SGs).2–4 In recent 
years, ultrasonography (US) of the parotid and submandibular 
glands has been widely used for identifying SG modifications 
in patients with primary Sjögren’s syndrome (pSS). In order to 
assess modifications in the SG echostructure in patients with SSc 
and compare them with those of patients with pSS or controls 
with sicca symptoms, we prospectively enrolled patients with 
SSc fulfilling the American College of Rheumatology/European 
League against Rheumatism (ACR/EULAR) 2013 classification 
criteria, patients with pSS according to the ACR/EULAR 2016 
classification criteria, and controls with sicca symptoms. Bilateral 
parotid and submandibular ultrasound was performed on every 
patient by the same operator (MC) blinded to the diagnosis. The 
inhomogeneity of each of the four major SGs in B-mode was 
graded using the Cornec et al scoring system (scale of 0 to 4) as 
previously described.5 The highest grade among the four glands 
was suggestive of Sjögren’s syndrome if ≥2.
A total of 108 patients were included in the study: SSc 
(n=25), pSS (n=48) and controls (n=35). The character-
istics of the patients are shown in table 1. When comparing 
the pSS and controls, the performance of an US echostructure 
grade ≥2 for the diagnosis of pSS was good (sensitivity: 75%, 
specificity: 91.4%, positive predictive value: 92.3%, negative 
predictive value: 72.7%). Among the 25 patients with SSc, 9 
had a history of or had a current digital ulcer, 8 had interstitial 
lung disease, 6 received an immunosuppressant (methotrexate 
(n=4), mycophenolate mofetil (n=2)), 2 received hydroxy-
chloroquine, and 5 received glucocorticoids (all at a daily dose 
≤10 mg), 40% complained of xerostomia and 36% of xeroph-
thalmia, Schirmer’s test was ≤5 mm in 5 min in 9/17 (53%), 
and 8/17 (47.1%) had an unstimulated salivary flow ≤0.1 mL/
minute. The lengths of parotid and submandibular glands were 
smaller in patients with SSc versus controls after adjustemnt 
for age and sex (p=0.02 and p=0.04, respectively). In the 
SSc group, 7 (28%) had a salivary gland ultrasound (SGUS) 
grade ≥2 (n=5, grade 3; n=2, grade 4). Five (71%) of the 7 
patients with SSc with SGUS grade ≥2 were anticentromere 
antibody (ACA)-positive compared with 4/18 (22%) patients 
with SSc with SGUS scores of 0–1 (p=0.02). None of these 
seven patients with US abnormalities suggestive of pSS had 
anti-Ro 60/SSA or La/SSB antibodies.
To date, this is the first study assessing morphological echo-
structure modifications of the major SGs in patients with 
SSc. According to our results, more than a quarter of patients 
with SSc, especially those with ACA, had inhomogeneity of 
the parotid and submandibular parenchyma that is evocative 
of pSS. We cannot exclude that the SGUS inhomogeneity is a 
SSc-related manifestation, especially in patients with SSc with 
ACA. These observations could more probably represent a 
distinct ACA-positive SSc/Sjögrenoverlap syndrome, as previ-
ously described, that salivary gland ultrasound could identify 
in a simple and non-invasive way.6
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Table 1 Clinical and biological characteristics of the patients
Characteristics SSc (n=25) pSS (n=48) Controls (n=35)
Age, years, mean±SD 64.8±9.5 62.1±12.4 55±15
Female, n (%) 22 (88) 46 (95) 34 (97)
Disease duration, years 10.6±11.3 10.6±7.8 6.5±6.3
Treatments       
Immunosuppressive 
therapy, n (%)
7 (28) 4 (8.3) 2 (5.7)
Hydroxychloroquine, n (%) 2 (8) 12(25) 4 (11.4)
Glucocorticoids, n (%) 5 (20) 5 (10.4) 2 (5.9)
Clinical signs       
Xerostomia, n (%) 10 (40) 48 (100) 30 (85)
Xerophthalmia, n (%) 9 (36) 43 (89) 29 (82)
Clinical parotid 
enlargement, n (%)
0 3 (6.4) 2 (5.7)
Raynaud phenomenon, 
n (%)
25 (100) 6 (12.5) 5 (14.3)
Inflammatory arthralgia, 
n (%)
14 (56) 11 (22.9) 30 (85.7)
Laboratory tests       
Schirmer’s test ≤5 mm, 
n (%)
9/17 (53) 38/47 (80.9) 8/32 (25)
Unstimulated salivary flow 
≤0.1 mL/min, n (%)
8/17 (47.1) 41/47 (87.2) 16/33 (49.5)
ANA≥1/160, n (%) 24 (96) 36 (75) 17 (49)
Anti-Ro 52/SSA, n (%) 4 (16) 24 (50) 2 (5.7)
Anti-Ro 60/SSA, n (%) 2 (8) 26 (54) 0
Anti-La/SSB, n (%) 0 14 (29.2) 0
Rheumatoid factor, n (%) 3/22 (14) 16/39 (41) 2/35 (5.7)
Antitopoisomerase, n (%) 10 (40) 1 (2.1) 0
ACA, n (%) 9 (36) 3 (6.3) 0
ESR, med (Q1–Q3), mm at 
first hour
16(11-21) 11(6-28) 8(5-14)
CRP, mean (Q1–Q3), mg/L 2.9 (2.9–8) 2.9 (0.5–3.8) 2.9 (0–6.5)
Focus score ≥1 (labial 
salivary gland), n (%)
41/46 (89) 3/27 (11)
SGUS features       
Parotid length, mean±SD, 
mm
41.5±7.8 42.5±6.5 45.9±5.2
Parotid width, mean±SD, 
mm
37±5.8 35.8±6.5 39±5.9
Submandibular surface 
area, mean±SD, cm2
2±0.8 1.8±0.5 2.2±0.7
Submandibular length, 
mean±SD, mm
26.7±5.8 28.4±5.7 30.1±4.3
US grade max, n (%)       
  0 or 1 18 (72) 12 (25) 32 (91.4)
  ≥2 7 (28) 36 (75) 3 (8.6)
ACA, anticentromere antibody; ANA, antinuclear antibody; CRP, C reactive protein; 
ESR, erythrocyte sedimentation rate;SGUS, Salivary gland ultrasound; SSA, 
Sjögren's-Syndrome-related-antigen type A antibody; SSB, Sjögren's-syndrome-
related-antigen type B antibody; SSc, systemic sclerosis;US, ultrasonography; pSS, 
primary Sjögren’s syndrome.
 o
n
 N
ovem
ber 2, 2019 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2019-215777 on 12 June 2019. Downloaded from
 
2 Ann Rheum Dis Month 2019 Vol 0 No 0
Correspondence
final approval. SM: contribution to the conception and interpretation of the data, 
revising and final approval. BP: contribution to the conception, statistical analysis 
and interpretation of the data, revising and final approval. MS: contribution to 
the conception and interpretation of the data, revising and final approval. JJD: 
conception and design of the work, interpretation of the data, drafting the work, 
revising and final approval.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval French CPP n°AU1292-07/10/2016, ANSM n°2016-A01256-45.
Provenance and peer review Not commissioned; internally peer reviewed.
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and 
permissions. Published by BMJ.
To cite Couderc M, Tournadre A, Mathieu S, et al. Ann Rheum Dis Epub ahead of 
print: [please include Day Month Year]. doi:10.1136/annrheumdis-2019-215777
Received 24 May 2019
Accepted 25 May 2019
Ann Rheum Dis 2019;0:1–2. doi:10.1136/annrheumdis-2019-215777
RefeRences
 1 Ferdowsi N, Huq M, Stevens W, et al. Development and validation of the scleroderma 
clinical Trials Consortium damage index (SCTC-DI): a novel instrument to quantify 
organ damage in systemic sclerosis. Ann Rheum Dis 2019;78:807–16.
 2 Kobak S, Oksel F, Aksu K, et al. The frequency of sicca symptoms and Sjögren’s 
syndrome in patients with systemic sclerosis. Int J Rheum Dis 2013;16:88–92.
 3 Avouac J, Sordet C, Depinay C, et al. Systemic sclerosis-associated Sjögren’s syndrome 
and relationship to the limited cutaneous subtype: results of a prospective study of 
sicca syndrome in 133 consecutive patients. Arthritis Rheum 2006;54:2243–9.
 4 Avouac J, Airò P, Dieude P, et al. Associated autoimmune diseases in systemic sclerosis 
define a subset of patients with milder disease: results from 2 large cohorts of 
European Caucasian patients. J Rheumatol 2010;37:608–14.
 5 Cornec D, Jousse-Joulin S, Pers J-O, et al. Contribution of salivary gland ultrasonography 
to the diagnosis of Sjögren’s syndrome: toward new diagnostic criteria? Arthritis 
Rheum 2013;65:216–25.
 6 Baldini C, Mosca M, Della Rossa A, et al. Overlap of ACA-positive systemic sclerosis and 
Sjögren’s syndrome: a distinct clinical entity with mild organ involvement but at high 
risk of lymphoma. Clin Exp Rheumatol 2013;31:272–80.
 o
n
 N
ovem
ber 2, 2019 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2019-215777 on 12 June 2019. Downloaded from
 
